Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Silver vs non‐antibacterial Adverse events · people with burns Antiseptics for burns (2017) · Cochrane | no estimate extracted | NR | No studies |
PAAP plus education vs education alone Serious adverse events (including death). · adults with asthma Personalised asthma action plans for adults with asthma (2017) · Cochrane | no estimate extracted | NR | No studies |
PAAP plus education vs education alone Lung function. · adults with asthma Personalised asthma action plans for adults with asthma (2017) · Cochrane | no estimate extracted | NR | No studies |
PAAP plus education vs education alone Days lost from work or study. · adults with asthma Personalised asthma action plans for adults with asthma (2017) · Cochrane | no estimate extracted | NR | No studies |
Postoperative MMC‐EMDA induction vs MMC‐PD induction therapy Disease‐specific quality of life ‐ not reported Intravesical electromotive drug administration for non‐muscle invasive bladder cancer (2017) · Cochrane | no estimate extracted | NR | No studies |
Postoperative MMC‐EMDA with sequential BCG induction and maintenance vs postoperative BCG induction and maintenance therapy Disease‐specific quality of life ‐ not reported Intravesical electromotive drug administration for non‐muscle invasive bladder cancer (2017) · Cochrane | no estimate extracted | NR | No studies |
Single‐dose, preoperative MMC‐EMDA vs single‐dose, postoperative MMC‐PD Disease‐specific quality of life ‐ not reported Intravesical electromotive drug administration for non‐muscle invasive bladder cancer (2017) · Cochrane | no estimate extracted | NR | No studies |
Single‐dose, preoperative MMC‐EMDA vs TURBT alone Disease‐specific quality of life ‐ not reported Intravesical electromotive drug administration for non‐muscle invasive bladder cancer (2017) · Cochrane | no estimate extracted | NR | No studies |
Postoperative MMC‐EMDA induction vs postoperative BCG induction therapy Disease‐specific quality of life ‐ not reported Intravesical electromotive drug administration for non‐muscle invasive bladder cancer (2017) · Cochrane | no estimate extracted | NR | No studies |
Insulin Aspart (+ NPH) vs human insulin (+ NPH insulin) Macrosomia · pregnant women with pre‐existing diabetes Different insulin types and regimens for pregnant women with pre‐existing diabetes (2017) · Cochrane | no estimate extracted | NR | No studies |
Insulin Aspart (+ NPH) vs human insulin (+ NPH insulin) Perinatal death · pregnant women with pre‐existing diabetes Different insulin types and regimens for pregnant women with pre‐existing diabetes (2017) · Cochrane | no estimate extracted | NR | No studies |
Insulin Aspart (+ NPH) vs human insulin (+ NPH insulin) Pre‐eclampsia · pregnant women with pre‐existing diabetes Different insulin types and regimens for pregnant women with pre‐existing diabetes (2017) · Cochrane | no estimate extracted | NR | No studies |
Insulin Aspart (+ NPH) vs human insulin (+ NPH insulin) Caesarean section · pregnant women with pre‐existing diabetes Different insulin types and regimens for pregnant women with pre‐existing diabetes (2017) · Cochrane | no estimate extracted | NR | No studies |
Insulin Aspart (+ NPH) vs human insulin (+ NPH insulin) Fetal anomaly · pregnant women with pre‐existing diabetes Different insulin types and regimens for pregnant women with pre‐existing diabetes (2017) · Cochrane | no estimate extracted | NR | No studies |
Insulin Aspart (+ NPH) vs human insulin (+ NPH insulin) Birth trauma including shoulder dystocia, nerve palsy and fracture · pregnant women with pre‐existing diabetes Different insulin types and regimens for pregnant women with pre‐existing diabetes (2017) · Cochrane | no estimate extracted | NR | No studies |
Insulin Aspart (+ NPH) vs human insulin (+ NPH insulin) Composite outcome measure of neonatal morbidity · pregnant women with pre‐existing diabetes Different insulin types and regimens for pregnant women with pre‐existing diabetes (2017) · Cochrane | no estimate extracted | NR | No studies |
Computer‐based interventions vs in‐person interventions Burnout · employees Computer‐based versus in‐person interventions for preventing and reducing stress in workers (2017) · Cochrane | no estimate extracted | NR | No studies |
Fibrin glue vs Bascom's procedure Time to healing (days) · adults with pilonidal sinus Fibrin glue for pilonidal sinus disease (2017) · Cochrane | no estimate extracted | NR | No studies |
Fibrin glue vs Bascom's procedure Adverse events (seroma or allergic reaction) · adults with pilonidal sinus Fibrin glue for pilonidal sinus disease (2017) · Cochrane | no estimate extracted | NR | No studies |
Karydakis flap plus fibrin glue vs Karydakis flap and drain Time to healing (days) · Men with pilonidal sinus Fibrin glue for pilonidal sinus disease (2017) · Cochrane | no estimate extracted | NR | No studies |
NMA evidence for individual network: proportion with complete healing ‐ interventions vs saline gauze Contrasts: interventions versus saline gauze · people with pressure ulcers Dressings and topical agents for treating pressure ulcers (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Elimination of all clinical signs of ocular surface inflammation ('complete success'), preferably measured by a composite grading system, at three months (± one month) after start of treatment · children with blepharokeratoconjunctivitis Topical treatments for blepharokeratoconjunctivitis in children (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Uncontrolled or poorly controlled disease progression due to treatment failure, at three months (± one month) after start of treatment · children with blepharokeratoconjunctivitis Topical treatments for blepharokeratoconjunctivitis in children (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life · children with blepharokeratoconjunctivitis Topical treatments for blepharokeratoconjunctivitis in children (2017) · Cochrane | no estimate extracted | NR | No studies |
Oral anti‐diabetic pharmacological therapies vs placebo ‐ neonatal outcomes Death or serious morbidity composite ‐ not reported · infants of women diagnosed with gestational diabetes Oral anti‐diabetic pharmacological therapies for the treatment of women with gestational diabetes (2017) · Cochrane | no estimate extracted | NR | No studies |
Oral anti‐diabetic pharmacological therapies vs placebo ‐ neonatal outcomes Adiposity (neonate, child, adult) ‐ not measured · infants of women diagnosed with gestational diabetes Oral anti‐diabetic pharmacological therapies for the treatment of women with gestational diabetes (2017) · Cochrane | no estimate extracted | NR | No studies |
Oral anti‐diabetic pharmacological therapies vs placebo ‐ neonatal outcomes Diabetes (child, adult) ‐ not measured · infants of women diagnosed with gestational diabetes Oral anti‐diabetic pharmacological therapies for the treatment of women with gestational diabetes (2017) · Cochrane | no estimate extracted | NR | No studies |
Oral anti‐diabetic pharmacological therapies vs placebo ‐ neonatal outcomes Neurosensory disability in later childhood ‐ not measured · infants of women diagnosed with gestational diabetes Oral anti‐diabetic pharmacological therapies for the treatment of women with gestational diabetes (2017) · Cochrane | no estimate extracted | NR | No studies |
Metformin vs glibenclamide ‐ maternal outcomes Development of type 2 diabetes ‐ not measured · women diagnosed with gestational diabetes Oral anti‐diabetic pharmacological therapies for the treatment of women with gestational diabetes (2017) · Cochrane | no estimate extracted | NR | No studies |
Metformin vs glibenclamide ‐ maternal outcomes Return to pre‐pregnancy weight ‐ not measured · women diagnosed with gestational diabetes Oral anti‐diabetic pharmacological therapies for the treatment of women with gestational diabetes (2017) · Cochrane | no estimate extracted | NR | No studies |
Metformin vs glibenclamide ‐ maternal outcomes Postnatal depression ‐ not measured · women diagnosed with gestational diabetes Oral anti‐diabetic pharmacological therapies for the treatment of women with gestational diabetes (2017) · Cochrane | no estimate extracted | NR | No studies |
Metformin vs glibenclamide ‐ neonatal outcomes Adiposity ‐ not measured · Infants of women diagnosed with gestational diabetes Oral anti‐diabetic pharmacological therapies for the treatment of women with gestational diabetes (2017) · Cochrane | no estimate extracted | NR | No studies |
Metformin vs glibenclamide ‐ neonatal outcomes Diabetes ‐ not measured · Infants of women diagnosed with gestational diabetes Oral anti‐diabetic pharmacological therapies for the treatment of women with gestational diabetes (2017) · Cochrane | no estimate extracted | NR | No studies |
Metformin vs glibenclamide ‐ neonatal outcomes Neurosensory disability in later childhood ‐ not measured · Infants of women diagnosed with gestational diabetes Oral anti‐diabetic pharmacological therapies for the treatment of women with gestational diabetes (2017) · Cochrane | no estimate extracted | NR | No studies |
Glibenclamide vs acarbose ‐ maternal outcomes Hypertensive disorders of pregnancy ‐ not reported · women diagnosed with gestational diabetes; 11 to 33 weeks' gestation; singleton pregnancy Oral anti‐diabetic pharmacological therapies for the treatment of women with gestational diabetes (2017) · Cochrane | no estimate extracted | NR | No studies |
Oral anti‐diabetic pharmacological therapies vs placebo ‐ maternal outcomes Development of type 2 diabetes ‐ not measured · women diagnosed with gestational diabetes; 24‐30 weeks' gestation; singleton pregnancy. Oral anti‐diabetic pharmacological therapies for the treatment of women with gestational diabetes (2017) · Cochrane | no estimate extracted | NR | No studies |
Glibenclamide vs acarbose ‐ maternal outcomes Development of type 2 diabetes ‐ not reported · women diagnosed with gestational diabetes; 11 to 33 weeks' gestation; singleton pregnancy Oral anti‐diabetic pharmacological therapies for the treatment of women with gestational diabetes (2017) · Cochrane | no estimate extracted | NR | No studies |
Glibenclamide vs acarbose ‐ maternal outcomes Perineal trauma ‐ not reported · women diagnosed with gestational diabetes; 11 to 33 weeks' gestation; singleton pregnancy Oral anti‐diabetic pharmacological therapies for the treatment of women with gestational diabetes (2017) · Cochrane | no estimate extracted | NR | No studies |
Glibenclamide vs acarbose ‐ maternal outcomes Return to pre‐pregnancy weight ‐ not reported · women diagnosed with gestational diabetes; 11 to 33 weeks' gestation; singleton pregnancy Oral anti‐diabetic pharmacological therapies for the treatment of women with gestational diabetes (2017) · Cochrane | no estimate extracted | NR | No studies |
Glibenclamide vs acarbose ‐ maternal outcomes Postnatal depression ‐ not reported · women diagnosed with gestational diabetes; 11 to 33 weeks' gestation; singleton pregnancy Oral anti‐diabetic pharmacological therapies for the treatment of women with gestational diabetes (2017) · Cochrane | no estimate extracted | NR | No studies |
Glibenclamide vs acarbose ‐ maternal outcomes Induction of labour ‐ not reported · women diagnosed with gestational diabetes; 11 to 33 weeks' gestation; singleton pregnancy Oral anti‐diabetic pharmacological therapies for the treatment of women with gestational diabetes (2017) · Cochrane | no estimate extracted | NR | No studies |
Glibenclamide vs acarbose ‐ neonatal outcomes Death or serious morbidity composite ‐ not reported · women with gestational diabetes Oral anti‐diabetic pharmacological therapies for the treatment of women with gestational diabetes (2017) · Cochrane | no estimate extracted | NR | No studies |
Glibenclamide vs acarbose ‐ neonatal outcomes Adiposity ‐ not reported · women with gestational diabetes Oral anti‐diabetic pharmacological therapies for the treatment of women with gestational diabetes (2017) · Cochrane | no estimate extracted | NR | No studies |
Glibenclamide vs acarbose ‐ neonatal outcomes Diabetes ‐ not reported · women with gestational diabetes Oral anti‐diabetic pharmacological therapies for the treatment of women with gestational diabetes (2017) · Cochrane | no estimate extracted | NR | No studies |
Glibenclamide vs acarbose ‐ neonatal outcomes Neurosensory disability in later childhood ‐ not reported · women with gestational diabetes Oral anti‐diabetic pharmacological therapies for the treatment of women with gestational diabetes (2017) · Cochrane | no estimate extracted | NR | No studies |
Oral anti‐diabetic pharmacological therapies vs placebo ‐ maternal outcomes Return to pre‐pregnancy weight ‐ not measured · women diagnosed with gestational diabetes; 24‐30 weeks' gestation; singleton pregnancy. Oral anti‐diabetic pharmacological therapies for the treatment of women with gestational diabetes (2017) · Cochrane | no estimate extracted | NR | No studies |
Oral anti‐diabetic pharmacological therapies vs placebo ‐ maternal outcomes Postnatal depression ‐ not measured · women diagnosed with gestational diabetes; 24‐30 weeks' gestation; singleton pregnancy. Oral anti‐diabetic pharmacological therapies for the treatment of women with gestational diabetes (2017) · Cochrane | no estimate extracted | NR | No studies |
Oral anti‐diabetic pharmacological therapies vs placebo ‐ neonatal outcomes Perinatal mortality · infants of women diagnosed with gestational diabetes Oral anti‐diabetic pharmacological therapies for the treatment of women with gestational diabetes (2017) · Cochrane | no estimate extracted | NR | No studies |
On‐demand deprescribing vs continued use Cost/resource use · people with moderate GERD and mild esophagitis, mean age 48 to 57 years Deprescribing versus continuation of chronic proton pump inhibitor use in adults (2017) · Cochrane | no estimate extracted | NR | No studies |
Lifestyle vs control ‐ Neonatal and later outcomes Adiposity (adult) not measured · Women with gestational diabetes Lifestyle interventions for the treatment of women with gestational diabetes (2017) · Cochrane | no estimate extracted | NR | No studies |